Unbound MEDLINE

Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Journal of drugs in dermatology : JDD. [J Drugs Dermatol] Journal article

 
TitleTazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Author(s)Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L 
InstitutionDepartment of Dermatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203-2098, USA. ashalita@downstate.edu
SourceJ Drugs Dermatol 2005 Mar-Apr; 4(2):153-8.
MeSHAcne Vulgaris
Adolescent
Adult
Dermatologic Agents
Double-Blind Method
Facial Dermatoses
Female
Humans
Male
Naphthalenes
Nicotinic Acids
Ointments
Research Support, Non-U.S. Gov't
AbstractA multicenter, double-blind, randomized, parallel-group trial compared tazarotene 0.1% cream with adapalene 0.1% cream, once daily for 12 weeks, in 173 patients with facial acne vulgaris. Tazarotene was associated with a significantly greater incidence of patients achieving 50% or greater global improvement (77% vs. 55%, P < or = .01), and a significantly greater reduction in comedo count (median of 68% vs. 36%, P < or =.001, compared with adapalene. A significant between-group difference in baseline inflammatory lesion count precluded a comparison of efficacy against inflammatory acne. The most common adverse events were dryness, peeling/flaking, itching, redness/erythema, burning, and facial irritation with comparable incidences of each between groups. Mean peeling and burning levels were milder with adapalene, though were trace or less in both groups throughout. There were no significant between-group differences in the incidence of patients discontinuing due to lack of efficacy or adverse events. Tazarotene cream offers significantly greater efficacy and comparable tolerability to adapalene cream.
Languageeng
Pub Type(s)Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
PubMed ID15776771
  
Advertise on this site.